Greenhaven Road Capital Backs Lifecore Biomedical for Monetizing Excess Capacity
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Lifecore Biomedical, Inc. (NASDAQ:LFCR) as a top-five holding due to the potential of monetizing excess manufacturing capacity. The company announced se